[1]张琳.ZD1839治疗晚期非小细胞肺癌的临床观察[J].南方医科大学学报,2004,(09):1061-1063.
 ZHANG Lin.Clinical observation of ZD1839 in treating 32 cases of non-small-cell lung cancer[J].,2004,(09):1061-1063.
点击复制

ZD1839治疗晚期非小细胞肺癌的临床观察()
分享到:

《南方医科大学学报》[ISSN:/CN:]

卷:
期数:
2004年09期
页码:
1061-1063
栏目:
出版日期:
2004-09-01

文章信息/Info

Title:
Clinical observation of ZD1839 in treating 32 cases of non-small-cell lung cancer
作者:
张琳
解放军第309医院呼吸科, 北京, 100091
Author(s):
ZHANG Lin
Department of Respiratory Disease, 309 Hospital of PLA, Beijing 100091, China
关键词:
ZD1839/副作用非小细胞肺癌/化学治疗疾病控制率表皮生长因子受体
Keywords:
ZD1839/adverse eventsnon-small-cell lung cancer/chemotherapydisease control ratesepidermal growth factor receptor (EGFR)
分类号:
R738.1
摘要:
目的 观察ZD1839治疗晚期非小细胞肺癌的疗效和毒副作用。方法 以一定的标准选取32例晚期非小细胞肺癌病人,口服ZD1839治疗,90 d后观察其疗效及毒副反应。结果 完全缓解(CR)0%,部分缓解(PR)18.75%,稳定(SD)37.50%,疾病控制率(CR+PR+SD)56.25%。毒副作用中,出现痤疮样皮疹10例(31.25%),腹泻6例(18.75%),转氨酶升高4例(12.50%),恶心、呕吐5例(15.63%),未发现间质性肺炎病例。结论 ZD1839是一种新药,其疾病控制率和毒副作用对于肺癌患者来说是可以接受的,在治疗肺癌方面具有良好的前景。
Abstract:
Objective To study e the therapeutic and adverse effects of ZD1839 in treating non-small-cell lung cancer (NSCLC). Methods The therapeutic and adverse effects of ZD1839 given orally were observed in 32 NSCLC cases after a treatment course more than 90 d. Results The rates of complete remission (CR), partial remission (PR), and stabilization (SD) were 0%, 18.75%, and 37.50% respectively, with a disease control rate of 56.25%. The adverse effects of this agent included acneiform rash, diarrhea, aminotransferase elevation, nausea and vomiting, occurring in 31.25%, 18.75%, 12.50% and 15.63% of the cases respectively. No interstitial lung disease was found. Conclusion ZD1839 is a new drug produeing acceptable disease control rate along with tolerable adverse effects in patients with lung cancer.

参考文献/References:

[1] 李新旭,周同冲,赵健.非小细胞肺癌骨转移综合治疗临床分析[J].第一军医大学学报,2003,23(7):752-3.Li XX, Zhou TC, Zhao J. Clinical evaluation of combined-modality therapy for bone metastasis of non-small-cell lung cancer[J]. J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao, 2003, 23(7): 752-3.
[2] 蔡红兵,代方国,闵清芬,等.中医药配合放疗治疗非小细胞肺癌的临床研究[J].第一军医大学学报,2002,22(12):1112-3.Cai HB, Dai FG, Min QF, et al. Clinical study of the effects of radiotherapy in combination with traditional Chinese medicine on nonsmall cell lung cancer[J]. J First Mil Med Univ/Di Yi JunYi Da Xue Xue Bao, 2002, 22(12): 1112-3.
[3] Sirotnak FM. Studies with ZD1839 in preclinical models[J]. Semin Oncol, 2003, 30 (1 Suppl 1): 12-20.
[4] Ritter CA, Arteaga CL. The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors[J]. Semin Oncol, 2003, 30 (1 Suppl 1): 3-11.
[5] Herbst RS. Dose-comparative monotherapytrials of ZD1839 inpreviously treated non-small cell lung cancer patients[J]. Semin Oncol,2003, 30(1 Suppl 1): 30-8.
[6] Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase Ⅱ trial ofgefitinib for previously treated patients with advanced non-small-cell lung cancer[J]. J Clin Oncol, 2003, 21(12):2237-46.
[7] Schiller JH. New directions for ZD1839 in the treatment of solid tumors[J]. Semin Oncol, 2003, 30(1 Suppl 1): 49-55.
[8] Baselga J, Rischin D, Ranson M. Phase Ⅰ safety, pharmacokinetic,and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types[J]. J Clin Oncol, 2002, 20(21): 4292-302.
[9] Lorusso PM. Phase Ⅰ studies of ZD1839 in patients with common solid tumors[J]. Semin Oncol, 2003, 30 (Suppl 1): 21-9.

备注/Memo

备注/Memo:
收稿日期:2004-1-21。
作者简介:张琳(1967-),男,2002年毕业于第一军医大学,硕士,主治医师,电话:010-66775065
更新日期/Last Update: 1900-01-01